
    
      This phase 3 clinical trial is designed as randomized, active-comparator, double-dummy,
      multi-center for ERD patients, who take YYD601 40mg or Nexium 40mg for 8 weeks. Each part is
      assessed by 'LA grade' measured through the endoscopy, target goal is to confirm the
      non-inferiority of YYD601 40mg to Nexium 40mg.
    
  